Axovant is accelerating the development of innovative gene therapy products that address serious neurological and neuromuscular diseases with significant unmet medical needs. We are currently studying gene therapy candidates for GM1 gangliosidosis, Tay-Sachs and Sandhoff diseases, and Parkinson’s disease in clinical trials and are working quickly to bring gene therapy candidates for other indications to patients in the clinic. We know that patients can’t wait, so neither will we. Source
No articles found.
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics and se...
Cancer Genetics, Inc. is an emerging leader in ...
We have used biochemical, molecular & cell biology and in vivo models to screen, i...
We have used biochemical, molecular & cell biol...
An emerging leader in the specialty pharmaceuticals industry, ANI Pharmaceuticals ...
An emerging leader in the specialty pharmaceuti...
Ardelyx is focused on enhancing the way people with cardiorenal diseases are treat...
Ardelyx is focused on enhancing the way people ...
Tyme Inc. is an emerging biotechnology company developing cancer therapeutics that...
Tyme Inc. is an emerging biotechnology company ...
Athenex is a global oncology focused biopharmaceutical company dedicated to the di...
Athenex is a global oncology focused biopharmac...
bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., h...
bluebird bio is pioneering gene therapy with pu...
REGENXBIO is a leading biotechnology company focused on the development, commercia...
REGENXBIO is a leading biotechnology company fo...
Orchard Therapeutics is a fully integrated commercial-stage biopharmaceutical comp...
Orchard Therapeutics is a fully integrated comm...
Assertio Therapeutics is committed to providing responsible solutions to advance p...
Assertio Therapeutics is committed to providing...
Join the National Investor Network and get the latest information with your interests in mind.